Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
Haydar Frangoul(Children’s Hospital at TriStar Centennial), Stephan A. Grupp(Children's Hospital of Philadelphia), Marina Cavazzana(Université Rennes 2), Paul Telfer(Queen Mary University of London), Franco Locatelli(Bambino Gesù Children's Hospital), Lyndsay Molinari, Damiano Rondelli(University of Illinois Chicago), Monica Bhatia(Columbia University Irving Medical Center), Mark C. Walters(UCSF Benioff Children's Hospital), Roland Meisel(Düsseldorf University Hospital), Kevin H.M. Kuo(University Health Network), Martin H. Steinberg(Boston Medical Center), Robert I. Liem(Lurie Children's Hospital), Stephan Lobitz(Gemeinschaftsklinikum Mittelrhein), Ami J. Shah(University of California, Los Angeles), Akshay Sharma(St. Jude Children's Research Hospital), Michael J. Eckrich(Levine Children's Hospital), Tina Liu, Suzan Imren(Fred Hutch Cancer Center), Selim Corbacioglu(Unknown), William Hobbs(Vertex Pharmaceuticals (United States)), Laurence Dedeken(Université Libre de Bruxelles), Laura Bower(Vertex Pharmaceuticals (United States)), Weiyu Zhou(Vertex Pharmaceuticals (United States)), Markus Y. Mapara(Sheba Medical Center), Mariane de Montalembert(Hôpital Necker-Enfants Malades), Donna A. Wall(University of Manitoba)
Cited by 3
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k